<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="letter"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Anaesthesiol Clin Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">J Anaesthesiol Clin Pharmacol</journal-id><journal-id journal-id-type="publisher-id">JOACP</journal-id><journal-id journal-id-type="publisher-id">J Anaesthesiol Clin Pharmacol</journal-id><journal-title-group><journal-title>Journal of Anaesthesiology, Clinical Pharmacology</journal-title></journal-title-group><issn pub-type="ppub">0970-9185</issn><issn pub-type="epub">2231-2730</issn><publisher><publisher-name>Wolters Kluwer - Medknow</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">PMC9438819</article-id><article-id pub-id-type="publisher-id">JOACP-38-134</article-id><article-id pub-id-type="doi">10.4103/joacp.JOACP_38_21</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter to Editor</subject></subj-group></article-categories><title-group><article-title>Co-infections in patients with COVID: A case series</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tyagi</surname><given-names>Asha</given-names></name><xref rid="aff1" ref-type="aff"/><xref rid="cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><name><surname>Padhy</surname><given-names>Anurag</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Agrawal</surname><given-names>Ananya</given-names></name><xref rid="aff2" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Salhotra</surname><given-names>Rashmi</given-names></name><xref rid="aff1" ref-type="aff"/></contrib></contrib-group><aff id="aff1">Department of Anesthesiology and Critical Care, University College of Medical Sciences and GTB Hospital, New Delhi, India</aff><aff id="aff2"><label>&#x02020;</label>Hamdard Institute of Medical Sciences and Research, Delhi, India</aff><author-notes><corresp id="cor1">
<bold>Address for correspondence:</bold> Dr. Asha Tyagi, Department of Anesthesiology and Critical Care, University College of Medical Sciences and GTB Hospital, New Delhi, India. E-mail: <email xlink:href="drashatyagi@gmail.com">drashatyagi@gmail.com</email>
</corresp></author-notes><pub-date pub-type="ppub"><month>7</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>10</day><month>2</month><year>2022</year></pub-date><volume>38</volume><issue>Suppl 1</issue><fpage>S134</fpage><lpage>S135</lpage><history><date date-type="received"><day>19</day><month>1</month><year>2021</year></date><date date-type="accepted"><day>23</day><month>3</month><year>2021</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2022 Journal of Anaesthesiology Clinical Pharmacology</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncsalicense">https://creativecommons.org/licenses/by-nc-sa/4.0/</ali:license_ref><license-p>This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.</license-p></license></permissions></article-meta></front><body><p>Dear Editor,</p><p>Respiratory viruses may be associated with varying rates of microbial co-infections. There is previous evidence to show lack of bacterial co-infections following Middle East respiratory syndrome and only a small incidence with the severe acute respiratory syndrome-associated coronavirus-1.[<xref rid="R1" ref-type="bibr">1</xref>] We are reporting three patients of severe acute respiratory illness (fever and bilateral pneumonitis) with laboratory-confirmed (RT-PCR) COVID, who developed microbial co-infections. All had received protocolized pharmacological therapy including remdesivir/oral hydroxychloroquine, subcutaneous low molecular weight heparin, intravenous dexamethasone, prophylactic antibiotics as well as vitamin C and oral zinc supplementation in the ICU. All three patients had presented with raised total leucocytic count (TLC: 19,600; 23,600; and 23,400/mm<sup>3</sup>, respectively) in contrast to the expected immunosuppression and decreased TLC associated with COVID. The microbial organisms detected in the patients upon blood culture included <italic toggle="yes">Enterococcus faecium</italic> (sensitive to vancomycin, teicoplanin, and linezolid); <italic toggle="yes">Staphylococcus xylosus</italic> (resistant to erythromycin, ceftriaxone, ciprofloxacin, and tetracycline; sensitive to teicoplanin, vancomycin, linezolid, and cotrimoxazole) and non-albicans candida without any bacterial growth, respectively. An adequate response was seen with vancomycin in a patient with <italic toggle="yes">E. faecium</italic>, and with teicoplanin to <italic toggle="yes">S. xylosus</italic> as evidenced by an improvement in clinical condition, fall in TLC, and negative repeat blood cultures. The patient with candidemia, however, succumbed to COVID-induced acute respiratory distress syndrome within next couple of days.</p><p>A systematic review showed a 14% incidence of laboratory-confirmed bacterial co-infection among the patients with COVID admitted to ICU.[<xref rid="R1" ref-type="bibr">1</xref>] Thus, our findings help to emphasize that co-infections in patients with COVID are a clinical problem. The bacterial organisms detected by us are not commonly encountered otherwise. <italic toggle="yes">E. faecium</italic> was reported as the least common of co-infections in COVID with an incidence of 1/3834 patients.[<xref rid="R1" ref-type="bibr">1</xref>] Within the <italic toggle="yes">Enterococcus</italic> species, only 10% of infections are constituted by <italic toggle="yes">E. faecium</italic>.[<xref rid="R2" ref-type="bibr">2</xref>] It is more likely to be seen in immunosuppressed, elderly, critically ill, those on mechanical ventilation or long-term antibiotic therapy, for causing infections and multi-systemic manifestations.[<xref rid="R2" ref-type="bibr">2</xref><xref rid="R3" ref-type="bibr">3</xref>] <italic toggle="yes">S. xylosus</italic>-induced sepsis also presents an uncommon occurrence. The organism is usually incriminated in infections among animals, with very few case reports amongst humans. It is a normal commensal on the skin and mucosa and becomes a cause of infections either as part of nosocomial pathology or in immunosuppressed individuals.[<xref rid="R4" ref-type="bibr">4</xref>] Lastly, invasive candidemia reported in the third case by us is also known to have a predisposition for immunosuppressed patients. Thus, it is possible that the microbial co-infections in COVID are preferential of flora that thrives in immunocompromised patients. It is interesting to note that all of these patients with co-infections during COVID illness presented with raised TLC, even though the neutrophil&#x02013;lymphocyte ratio was high and suggestive of COVID. There are previous data to show that raised TLC in COVID is associated with a poor prognosis.[<xref rid="R5" ref-type="bibr">5</xref>]</p><p>Thus, surveillance for microbial co-infections, even uncommon ones, is required in patients with COVID and the role of raised TLC remains pertinent for the same.</p><sec disp-level="2"><title>Financial support and sponsorship</title><p>Nil.</p></sec><sec sec-type="COI-statement" disp-level="2"><title>Conflicts of interest</title><p>There are no conflicts of interest.</p></sec></body><back><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author">
<name><surname>Lansbury</surname><given-names>L</given-names></name>
<name><surname>Lim</surname><given-names>B</given-names></name>
<name><surname>Baskaran</surname><given-names>V</given-names></name>
<name><surname>Lim</surname><given-names>WS</given-names></name>
</person-group><article-title>Co-infections in people with COVID-19: A systematic review and meta-analysis</article-title><source>J Infect</source><year>2020</year><volume>81</volume><fpage>266</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">32473235</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author">
<name><surname>Emori</surname><given-names>TG</given-names></name>
<name><surname>Gaynes</surname><given-names>RP</given-names></name>
</person-group><article-title>An overview of nosocomial infections, including the role of the microbiology laboratory</article-title><source>Clin Microbiol Rev</source><year>1993</year><volume>6</volume><fpage>428</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">8269394</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author">
<name><surname>Pinholt</surname><given-names>M</given-names></name>
<name><surname>Ostergaard</surname><given-names>C</given-names></name>
<name><surname>Arpi</surname><given-names>M</given-names></name>
</person-group><article-title>Danish Collaborative Bacteraemia Network (DACOBAN). Incidence, clinical characteristics and 30-day mortality of enterococcal bacteraemia in Denmark 2006-2009: A population-based cohort study</article-title><source>Clin Microbiol Infect</source><year>2014</year><volume>20</volume><fpage>145</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">23647880</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author">
<name><surname>Acuff</surname><given-names>NV</given-names></name>
<name><surname>LaGatta</surname><given-names>M</given-names></name>
<name><surname>Nagy</surname><given-names>T</given-names></name>
<name><surname>Watford</surname><given-names>WT</given-names></name>
</person-group><article-title>Severe dermatitis associated with spontaneous <italic toggle="yes">Staphylococcus xylosus</italic> infection in <italic toggle="yes">Rag-/-Tpl2-/-</italic> mice</article-title><source>Comp Med</source><year>2017</year><volume>67</volume><fpage>344</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">28830581</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>Y</given-names></name>
<name><surname>Nie</surname></name>
<name><surname>Hu</surname><given-names>K</given-names></name>
<name><surname>Wu</surname><given-names>XJ</given-names></name>
<name><surname>Zhang</surname><given-names>YT</given-names></name>
<name><surname>Wang</surname><given-names>MM</given-names></name>
<etal/>
</person-group><article-title>Abnormal immunity of non-survivors with COVID-19: Predictors for mortality</article-title><source>Infect Dis Poverty</source><year>2020</year><volume>9</volume><fpage>108</fpage><pub-id pub-id-type="pmid">32746940</pub-id></element-citation></ref></ref-list></back></article>
